Administer by intravenous infusion over a period of 60 minutes. Do not administer as a rapid or bolus injection. Compatible with commonly used infusion solutions.

Moxifloxacin inhibits bacterial DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication, transcription, repair, and recombination. This leads to disruption of bacterial DNA and cell death.

• •Hypersensitivity to moxifloxacin or other quinolone antibiotics.
• •History of tendon disorders or rupture associated with quinolone use.
• •Patients with congenital or documented acquired QT prolongation.
• •Uncorrected hypokalemia or hypomagnesemia.
• •History of clinically significant bradycardia, heart failure with reduced left ventricular ejection fraction, or history of symptomatic arrhythmias.
• •Concomitant administration with other QT-prolonging drugs.

Store below 30°C. Do not freeze. Protect from light. Keep out of the reach of children.

In the event of an acute overdose, symptomatic and supportive treatment should be initiated. ECG monitoring is advised due to the risk of QT prolongation. There is no specific antidote. Hemodialysis or peritoneal dialysis remove only a small amount of moxifloxacin.

Pregnancy Category C. Moxifloxacin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is excreted in human breast milk; therefore, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.